Royal Bank of Canada
SPRO icon

Royal Bank of Canada’s Spero Therapeutics SPRO Stock Holding History

Royal Bank of Canada’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,739
Closed -$17K – 7500
2025
Q2 		$17K Buy
+5,739
New +$8.26K ﹤0.01% 6323
2024
Q3 		– Sell
-1,959
Closed -$3K – 7400
2024
Q2 		$3K Buy
+1,959
New +$2.96K ﹤0.01% 6675
2024
Q1 		– Sell
-315
Closed – – 7554
2023
Q4 		$0 Buy
315
+15
+5% +$18 ﹤0.01% 7551
2023
Q3 		$0 Buy
+300
New +$416 ﹤0.01% 7554
2022
Q4 		– Sell
-43
Closed – – 7684
2022
Q3 		$0 Buy
+43
New +$43 ﹤0.01% 7834
2022
Q2 		– Sell
-196,097
Closed -$1.71M – 7693
2022
Q1 		$1.71M Buy
196,097
+13,502
+7% +$138K ﹤0.01% 3199
2021
Q4 		$2.92M Buy
182,595
+2,493
+1% +$39.6K ﹤0.01% 2830
2021
Q3 		$3.32M Buy
180,102
+177,945
+8,250% +$2.86M ﹤0.01% 2635
2021
Q2 		$30K Buy
2,157
+96
+5% +$1.34K ﹤0.01% 6346
2021
Q1 		$30K Buy
2,061
+924
+81% +$16.3K ﹤0.01% 6200
2020
Q4 		$22K Buy
1,137
+510
+81% +$7.95K ﹤0.01% 6022
2020
Q3 		$7K Buy
627
+98
+19% +$1.16K ﹤0.01% 6051
2020
Q2 		$7K Sell
529
-49
-8% -$550 ﹤0.01% 5958
2020
Q1 		$5K Sell
578
-618
-52% -$5.45K ﹤0.01% 6050
2019
Q4 		$12K Buy
1,196
+896
+299% +$9.66K ﹤0.01% 6079
2019
Q3 		$3K Buy
300
+100
+50% +$1.05K ﹤0.01% 6219
2019
Q2 		$2K Hold
200
– – ﹤0.01% 6600
2019
Q1 		$3K Buy
200
+184
+1,150% +$1.95K ﹤0.01% 6445
2018
Q4 		$0 Sell
16
-122
-88% -$988 ﹤0.01% 7089
2018
Q3 		$1K Buy
138
+33
+31% +$383 ﹤0.01% 6620
2018
Q2 		$2K Buy
105
+103
+5,150% +$1.32K ﹤0.01% 6268
2018
Q1 		$0 Sell
2
-64
-97% -$776 ﹤0.01% 6758
2017
Q4 		$1K Buy
+66
New +$810 ﹤0.01% 6418

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's SPRO Position: Q3 2025 in Review

Royal Bank of Canada sold out of Spero Therapeutics (SPRO) in Q3 2025, closing a stake of 5,739 shares — an estimated $17K sold.

Royal Bank of Canada first reported a position in SPRO in Q4 2017 and held it in 23 quarters. The position peaked at $3.32M in Q3 2021. 47 funds tracked by Wall St. Rank hold SPRO as of Q3 2025.

  • Royal Bank of Canada reported no remaining Spero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 5,739 Spero Therapeutics shares in Q3 2025, an estimated $17K.
  • Royal Bank of Canada first reported a position in Spero Therapeutics in Q4 2017 and held it in 23 quarters.
  • Royal Bank of Canada's Spero Therapeutics position peaked at $3.32M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2025.

Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.